TECHNOLOGY & FOCUS

---

SMARTECH has developed and patented a unique delivery system, a novel anhydrous topical delivery system for hydrophilic and lipophilic molecules. NSAIDS (Sodium Diclofenac, Naproxen and Aspirin) are the first group of APIs (Active Pharmaceutical Ingredients). The delivery system is designed to stabilize and solubilize these hydrophilic molecules in an anhydrous gel environment. This delivery system is being developed to carry a variety of active ingredients – and even combinations of actives, like Sodium Diclofenac and Lidocaine – into the skin for more efficacious pain management. Pain management options for consumers are badly needed, especially in this period of opiate abuse and limitations. Research has shown the delivery system may allow for maximum solubility for multiple actives, which is intended to lead to enhanced skin penetration and increased efficacy and tolerability while keeping the skin hydrated making our delivery system technology a valuable asset in pipeline development and strategic partnering. One of the key features of our SMARTDELIVERY™ technology is to remove as much drug as possible from the skin’s surface after an application. This is a key limitation of some old topical NSAID formulations like Voltaren® and Pennsaid®. The US FDA is keen to apply new updated delivery technologies to minimize the toxic exposure of APIs to consumers. 

Future R & D for SMARTECH’S SMARTDELIVERY Technology: SMARTECH has filed patents for Multi-Layered Liposomal nano-delivery technology that can include the API, Paclitaxel (PTX) for topical skin cancer applications. Paclitaxel (PTX) is among the most widely used anti-neoplastic agent with a wide range of anti-tumor activity especially against metastatic breast cancer, non-small-cell lung cancer, ovarian cancer, head and neck tumor, Kaposi’s sarcoma, and urologic malignancies. PTX in intravenous formulations suffers from a range of serious side effects. These untoward reactions can be minimized if the drug is directly applied at a carcinoma site topically as in case of skin cancer so that a lower amount of drug will reach the systemic circulation compared to intravenous route of administratio